A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine

Trial Profile

A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Avacopan (Primary) ; Azathioprine; Cyclophosphamide; Cyclophosphamide; Prednisone; Rituximab
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis
  • Focus Therapeutic Use
  • Acronyms ADVOCATE
  • Sponsors ChemoCentryx
  • Most Recent Events

    • 07 Nov 2017 According to a ChemoCentryx media release, this trial has surpassed 30% of its target patient enrollment.
    • 08 Aug 2017 According to a ChemoCentryx media release, enrollment in this trial is expected to complete in mid-2018.
    • 09 Jan 2017 According to a ChemoCentryx media release, the trial design was discussed in detail with both the U.S. FDA and European Medicines Agency (EMA), and agreement was reached on the design and goals of the trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top